Orexigen Therapeutics (OREX) Tops Q3 EPS by 7c, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Orexigen Therapeutics Reports Financial and Business Results for the Third Quarter Ended September 30, 2015
November 5, 2015 4:01 PM ESTSAN DIEGO, Nov. 5, 2015 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the third quarter ended September 30, 2015.
"In the first 12 months since the U.S. launch, we have been encouraged by gross demand for Contrave, with well over 500,000 prescriptions written by approximately 50,000 physicians," said Mike Narachi, CEO of Orexigen. "In the coming year, we expect the overall market for anti-obesity medicines to grow significantly year over year and for Contrave to continue to gain overall market share."
Recent Business Highlights:
According to IMS... More